Saama launches COVID-19 data collaboration

By Jenni Spinner contact

- Last updated on GMT

Image: Getty/AlexRatha
Image: Getty/AlexRatha

Related tags: COVID-19, Coronavirus, Saama Technologies, Data management, Clinical trial

The company’s EndPandemic National Data Consortium aims to integrate data from clinical trials to accelerate development of a cure for the virus.

Saama Technologies is offering up its artificial intelligence (AI) powered Life Science Analytics Cloud (LSAC) technology platform to help establish the consortium. The purpose is to bring together data from both current and future studies to slash the time required to discover a cure by as much as 50%.

According to the company, the LSAC platform will enable researchers to visualize, analyze and interrogate across all available programs.

Accelerating a cure

Suresh Katta, Saama Technologies CEO and founder, told Outsourcing-Pharma that LSAC is a unique technology tool that offers authoritative oversight of clinical studies, to help reduce the time, cost and complexity of the drug development process.

It seamlessly connects, ingests, integrates, and harmonizes data from disparate clinical study streams coming from most of the source systems (EDC, CTMS, eTMF, IVR, Safety and others) globally across patients, sites, and regions and CROs​,” Katta explained.

The underlying analytics platform provides solutions to tackle a variety of business applications for pharma in clinical development across study feasibility, clinical ops, data management, biostat, and medical review/monitoring functions​,” he added.

Katta also told us the “barrier-busting collaboration” made possible by the consortium will help bring together organizations already working on solutions to the pandemic.

Currently there is a lot of great research going on in the world to help mitigate the pandemic; multiple biopharmaceutical companies and respected organizations are embarking on clinical programs to repurpose existing interventions or discover new therapeutic options​,” he said. “The consortium will establish a secure environment for biopharmaceutical companies, academic researchers, and healthcare organizations to combine their data for analysis​.”

Further, Katta said, the more scientific minds joining the collective, the better.

We challenge all scientific personnel and technology companies to join the EndPandemic National Data Consortium to work together during this crisis to pool relevant data to find treatments—and hopefully a cure—for SARS-CoV-2​.”

Collaboration is essential

David Shulkin, ninth secretary of the US Department of Veterans Affairs, said it is vital for companies to collaborate and share data to help come up with viable treatments for COVID-19 in a timely manner.

"We won't find rapid solutions for the SARS-CoV-2 pandemic with our data remaining so fragmented​," he said. “To adequately address this pandemic, we must share data from clinical studies across the research, healthcare, and pharma communities​.”

Shulkin added, “By having comprehensive datasets and deep data analytics we will have the opportunity to make great progress​.”

Any companies or organizations interested in participating in the EndPandemic National Data Consortium in order to collaborate on solutions and accelerate development of treatments should reach out to Saama Technologies at 888.970.3550.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Related suppliers

Follow us


View more